The complaint, filed by a minority shareholder in Akcea, centers on Ionis’s handling of inotersen, a drug it developed with Glaxo Group Limited to treat a rare protein disorder called ATTR Amyloidosis. According to the complaint, Glaxo’s decision to abandon the joint effort left Ionis “scrambling” to find a new partner to commercialize the drug. Ionis ultimately used its...
To read the full article log in. To learn more about a subscription click here.